Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis

Objectives:. The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate ICU-, hospital-, mechanical ventilation-, and vasopressor-fr...

Full description

Bibliographic Details
Main Authors: Prabalini Rajendram, MD, Gretchen L. Sacha, PharmD, Omar Mehkri, MD, Xiaofeng Wang, PhD, Xiaozhen Han, MS, Vidula Vachharajani, MD, Abhijit Duggal, MD
Format: Article
Language:English
Published: Wolters Kluwer 2021-01-01
Series:Critical Care Explorations
Online Access:http://journals.lww.com/10.1097/CCE.0000000000000327

Internet

http://journals.lww.com/10.1097/CCE.0000000000000327

Similar Items